Kurosawa M, Okabe M, Kunieda Y, Asaka M
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Ann Hematol. 1995 Aug;71(2):83-7. doi: 10.1007/BF01699251.
In order to determine the relevance of the p53 tumor suppressor gene mutations in acute myelogenous leukemia (AML), we analyzed the p53 gene in genomic DNA of 18 unselected cases of AML by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing. We detected three cases (16.7%) with the p53 gene mutations showing only the mutant alleles; the high incidence in cases with loss of a whole chromosome 17 (two of three) contrasted with the low incidence in cases without abnormalities of chromosome 17 (one of 15). These cases containing the mutations of the p53 gene showed a poor prognosis. Although we analyzed a rather small series of patients, these findings suggest that the p53 gene mutations might be involved in the progression and prognosis of at least some cases of AML.
为了确定p53肿瘤抑制基因突变在急性髓性白血病（AML）中的相关性，我们通过聚合酶链反应-单链构象多态性（PCR-SSCP）和直接测序分析了18例未经选择的AML病例基因组DNA中的p53基因。我们检测到3例（16.7%）p53基因突变，仅显示突变等位基因；17号整条染色体缺失的病例中突变发生率高（3例中有2例），而17号染色体无异常的病例中突变发生率低（15例中有1例）。这些含有p53基因突变的病例预后较差。尽管我们分析的患者系列相对较小，但这些发现表明p53基因突变可能至少在某些AML病例的进展和预后中起作用。
